Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells

Department of Cardio-Thoracic Surgery, Zhuji Affiliated Hospital of Wenzhou Medical University, Zhuji 311800, Zhejiang, China

Special Issues: Advanced Big Data Analysis for Precision Medicine

Objective: To investigate the inhibitory effect of Icotinib on proliferation and epithelial-mesenchymal transition of A549 cells. Methods: A549 cells were treated with Icotinib of different concentrations. The morphology of the cells was observed by inverted phase contrast microscope. The effect of different concentrations of Icotinib on the proliferation inhibition rate of A549 cells was detected by MTT assay. Flow cytometry was used to detect effect of Icotinib on the apoptosis rate of A549 cells. ELISA assay was used to detect the expression of EMT-related proteins, E-cadherin, N-cadherin, Vimentin and fibronectin, in A549 cells cultured supernatant. Transwell assay was used to examine the effects of different concentrations of Icotinib on the migration and invasion abilities of A549 cells. Results: Morphological changes were observed after A549 cells exposed to different concentrations of Icotinib for 48 hours. The inhibition rate of proliferation for each treatment group increased from MTT assay results. Flow cytometry results showed that cell apoptosis rate was significantly increased. Expression of E-cadherin was up-regulated and expression of N-cadherin, Vimentin and fibronectin were down-regulated from ELISA results. A549 cell migration and invasion abilities were significantly suppressed by Icotinib at different concentrations. Conclusion: Icotinib inhibits A549 cell proliferation, migration and invasion in both concentration and time-dependent manners, in turn it promotes A549 cell apoptosis in the same way. Icotinib also inhibits epithelial-mesenchymal transition by regulating EMT-related proteins expression in A549 cells.
  Figure/Table
  Supplementary
  Article Metrics

Keywords Icotinib; non-small cell lung cancer; A549 cells; proliferation; epithelial-mesenchymal transition

Citation: Guohai Wang, Zhiyuan Hu. Icotinib inhibits proliferation and epithelial-mesenchymal transition of non-small cell lung cancer A549 cells. Mathematical Biosciences and Engineering, 2019, 16(6): 7707-7718. doi: 10.3934/mbe.2019386

References

  • 1. W. Chen, R. Zheng, P. D. Baade, et al., Cancer statistics in China, 2015, CA Cancer J. Clin., 66 (2016), 115–132.
  • 2. K. D. Miller, R. L. Siegel, C. C. Lin, et al., Cancer treatment and survivorship statistics, 2016, CA Cancer J. Clin., 66 (2016), 271–289.
  • 3. J. Su, J. Liao, L. Gao, et al., Analysis of small nucleolar RNAs in sputum for lung cancer diagnosis, Oncotarget, 7 (2016), 5131–5142.
  • 4. L. A. Torre, R. L. Siegel and A. Jemal, Lung Cancer Statistics, Adv. Exp. Med. Biol., 893 (2016), 1–19.
  • 5. B. Grigoriu, T. Berghmans and A. P. Meert, Management of EGFR mutated nonsmall cell lung carcinoma patients, Eur. Respir. J., 45 (2015), 1132–1141.
  • 6. M. Yu, Y. Chen, X. Li, et al., YAP1 contributes to NSCLC invasion and migration by promoting Slug transcription via the transcription co-factor TEAD, Cell Death Dis., 9 (2018), 464.
  • 7. D. N. Carney, Lung cancer--time to move on from chemotherapy, N. Engl. J. Med., 346 (2002), 126–128.
  • 8. T. Evans, Utility of hypertension as a surrogate marker for efficacy of antiangiogenic therapy in NSCLC, Anticancer Res., 32 (2012), 4629–4638.
  • 9. F. R. Hirsch, M. Varella-Garcia and F. Cappuzzo, Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer, Oncogene, 28 Suppl 1 (2009), S32–37.
  • 10. M. Santarpia, I. Magri, M. Sanchez-Ronco, et al., mRNA expression levels and genetic status of genes involved in the EGFR and NF-kappaB pathways in metastatic non-small-cell lung cancer patients, J. Transl. Med., 9 (2011), 163.
  • 11. S. Thongprasert, E. Duffield, N. Saijo, et al., Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS), J. Thorac. Oncol., 6 (2011), 1872–1880.
  • 12. M. Maemondo, A. Inoue, K. Kobayashi, et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N. Engl. J. Med., 362 (2010), 2380–2388.
  • 13. A. Gu, C. Shi, L. Xiong, et al., Efficacy and safety evaluation of icotinib in patients with advanced non-small cell lung cancer, Chin. J. Cancer Res.,25 (2013), 90–94.
  • 14. G. Yang, Y. Yao, J. Zhou, et al., Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer, Oncol. Rep., 27 (2012), 2066–2072.
  • 15. H. P. Wang, L. Zhang, Y. X. Wang, et al., Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer, Chin. Med. J. (Engl)., 124 (2011), 1933.
  • 16. X. Mu, Y. Zhang, X. Qu, et al., Ubiquitin ligase Cbl-b is involved in icotinib (BPI-2009H)-induced apoptosis and G1 phase arrest of EGFR mutation-positive non-small-cell lung cancer, Biomed. Res. Int., 2013 (2013), 726375.
  • 17. X. Sun, Y. Xu, Y. Wang, et al., Synergistic Inhibition of Thalidomide and Icotinib on Human Non-Small Cell Lung Carcinomas Through ERK and AKT Signaling, Med. Sci. Monit., 24 (2018), 3193–3203.
  • 18. J. Lim and J. P. Thiery, Epithelial-mesenchymal transitions: insights from development, Development, 139 (2012), 3471–3486.
  • 19. J. P. Thiery, Epithelial-mesenchymal transitions in tumour progression, Nat. Rev. Cancer, 2 (2002), 442–454.
  • 20. J. P. Thiery, H. Acloque, R. Y. Huang, et al., Epithelial-mesenchymal transitions in development and disease, Cell, 139 (2009), 871–890.
  • 21. G. R. Oxnard, Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer, Arch. Pathol. Lab. Med., 136 (2012), 1205–1209.
  • 22. M. S. Tsao, A. Sakurada, J. C. Cutz, et al., Erlotinib in lung cancer-molecular and clinical predictors of outcome, N. Engl. J. Med., 353 (2005), 133–144.
  • 23. Q. Zhao, J. Shentu, N. Xu, et al., Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors, Lung Cancer, 73 (2011), 195–202.
  • 24. Y. Zhang, X. Meng, H. Shi, et al., The role of JAK/STAT3 signaling pathway on apoptosis of lung adenocarcinoma cell line PC-9 induced by icotinib, Am. J. Transl. Res., 8 (2016), 1730–1737.
  • 25. L. Ma, X. H. Han, S. Wang, et al., Effects of icotinib hydrochloride on the proliferation and apoptosis of human lung cancer cell lines, Zhonghua Yi Xue Za Zhi, 92 (2012), 2561–2564.
  • 26. D. S. Wang, A. Patel, S. Shukla, et al., Icotinib antagonizes ABCG2-mediated multidrug resistance, but not the pemetrexed resistance mediated by thymidylate synthase and ABCG2, Oncotarget, 5 (2014), 4529–4542.
  • 27. K. Chen, Q. Pan, Y. Gao, et al., DMS triggers apoptosis associated with the inhibition of SPHK1/NF-kappaB activation and increase in intracellular Ca2+ concentration in human cancer cells, Int. J. Mol. Med., 33 (2014), 17–24.

 

Reader Comments

your name: *   your email: *  

© 2019 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved